查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553571

基因转移技术市场规模、份额、趋势分析报告：按模式、按应用、按方法、按地区、细分市场预测，2024-2030

Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (AAV, Lentivirus, Retrovirus), By Application (Gene Therapy, Cell Therapy), By Method (Ex-vivo, In-vivo), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

基因转移技术市场的成长和趋势

Grand View Research, Inc.最新报告显示，到2030年，全球基因转移技术市场规模预计将达到102.7亿美元，2024年至2030年复合年增长率为11.4%。

病毒载体的技术进步、先进疗法的不断增加以及先进治疗产品的监管核准数量不断增加是市场的关键驱动力。

几种用于遗传改变的新工具已经被引入，使科学界更容易在基因组层面上揭示疾病的复杂性，从而导致新的基因转移方法的出现。此外，正在研究开发临床相关载体，包括病毒和非病毒载体，以先进的治疗方法对抗癌症和阿兹海默症慢性疾病，从而刺激市场收益。

该领域增加的投资和融资以支持各种基因转移方法的研究、开发和製造，进一步加速了收益成长。目前约 70% 的基因和细胞治疗项目是基于病毒载体，导致生物递送技术的有机收益成长。营运商正在进行大量投资，以扩大其病毒载体生产能力并满足不断增长的需求。

考虑到理化基因传递方法不断扩大的商机，主要参与企业正在加紧努力扩大业务。例如，奈米粒子由于其可调节的形态和生物行为，已证明其作为临床应用的有前途的载体的效率。此类新兴市场的发展预计将在未来几年加速该市场的收益成长。

基因转移技术市场报告亮点

  • 生物基因转殖技术因其高效性和特异性而在临床应用中广泛应用，并将在2023年占据该领域最大的收益占有率。
  • 由于危及生命的疾病的治疗方法方案不断扩大，加上最近 CAR-T 疗法的成功，基因疗法的开发将成为 2023 年市场上主要的产生收入应用。
  • 最近的 SARS-CoV-2 爆发也刺激了全球对基于病毒载体的疫苗研发的投资，以对抗该病毒，预计这将推动该领域的成长。
  • 体外由于其转导效率高、免疫抗原性反应低等优点占据了主要的销售份额。
  • 然而，体内和体外在慢性疾病的治疗方面都取得了临床成功，这两个领域都有望在未来几年实现良好的成长。
  • 由于美国拥有大量的生技公司和有利的法规环境，北美在收益方面占据全球市场的主导地位。
  • 同时，预计亚太地区在预测期内将以最快的速度成长。
  • 由于亚洲国家的工厂扩张和新基地建设，CDMO 和病毒载体的製造环境不断变化，正在刺激该地区载体的采用。
  • 主要参与企业正在与治疗开发商合作，以支持产品开发过程。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 全球基因转殖技术市场的变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球基因转殖技术市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 全球基因转殖技术市场：依模式估算及趋势分析

  • 细分仪表板
  • 全球基因转殖技术市场：模式变异分析，百万美元，2023 年和 2030 年
  • 生物
  • 化学
  • 身体的

第五章 全球基因转殖技术市场：按应用、估算与趋势分析

  • 细分仪表板
  • 全球基因转殖技术市场：应用变异分析，百万美元，2023 年和 2030 年
  • 基因治疗
  • 细胞疗法
  • 疫苗
  • 研究

第六章 全球基因转殖技术市场：方法估算及趋势分析

  • 细分仪表板
  • 全球基因转殖技术市场：方法变异分析，百万美元，2023 年和 2030 年
  • ex vivo
  • in vivo
  • in vitro

第七章 全球基因转殖技术市场：区域估计与趋势分析

  • 2023 年和 2030 年全球基因转移技术市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Horizon Discovery Ltd.
    • OriGene Technologies, Inc.
    • Oxford Biomedica PLC
    • SignaGen Laboratories
    • Flash Therapeutics
    • Takara Bio Inc.
    • Bio-Rad Laboratories, Inc.
    • System Biosciences, LLC.
    • Promega Corporation.
    • F. Hoffmann-La Roche Ltd
    • SIRION BIOTECH GmbH
    • Catalent, Inc.
简介目录
Product Code: GVR-4-68039-291-1

Gene Delivery Technologies Market Growth & Trends:

The global gene delivery technologies market size is expected to reach USD 10.27 billion by 2030, expanding at a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.

Several novel tools are being introduced for genetic alterations that have facilitated the scientific community to delineate the disease intricacies at the genomic level, leading to the emergence of novel gene delivery approaches. Furthermore, ongoing research to develop clinically relevant vectors including viral and non-viral vectors to combat chronic illnesses such as cancer, Alzheimer's, and others through advanced therapies is spurring the market revenue.

An increase in investment and financing in the space to support the research, development, and manufacturing of various modes of gene transfer further accelerates the revenue growth. Currently, around 70% of gene and cell therapy programs are based on viral vectors leading to organic revenue growth for biological delivery technologies. The operating players are investing significantly to scale up their viral vector manufacturing capability and meet the growing demand.

Considering growing opportunities in physio-chemical gene delivery approaches, key players are making focused efforts to boost their business presence. For instance, nanoparticles have proven their efficiency as promising vehicles for clinical usage owing to their tunable morphology, and biological behaviors. Such ongoing developments in the space are anticipated to accelerate revenue growth in this market in the coming years.

Gene Delivery Technologies Market Report Highlights:

  • The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment's largest revenue share in 2023
  • Gene therapy development is the key revenue-generating application in the 2023 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies
  • The recent pandemic of SARS-CoV-2 has also resulted in substantial global investments in R&D of viral vector-based vaccine to combat the virus, resulting in lucrative growth of this segment
  • The ex vivo method accounted for the major revenue share owing to its advantages such as high transduction efficiency and less immunogenic responses
  • However, both in vivo and ex vivo have shown clinical success in the treatment of chronic conditions, thus both segments are expected to witness lucrative growth in the coming years
  • Given the high number of biotech companies and a favorable regulatory environment in the U.S.; North America dominated the global market in terms of revenue
  • On the other hand, Asia Pacific is projected to grow at the fastest pace during the forecast period
  • Constantly evolving CDMO and viral vector manufacturing landscapes through plant expansions and new sites being built across the Asian countries is spurring the adoption of vectors in this region
  • The key players are engaged in collaboration with therapy developers to support their product development process

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Gene Delivery Technology Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Gene Delivery Technology Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Gene Delivery Technology Market: Mode Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Gene Delivery Technology Market: Mode Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Biological
    • 4.3.1. Biological Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Adenovirus
      • 4.3.2.1. Adenovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Retrovirus
      • 4.3.3.1. Retrovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. AAV
      • 4.3.4.1. AAV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Lentivirus
      • 4.3.5.1. Lentivirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Other Viruses
      • 4.3.6.1. Other Viruses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.7. Non-viral
      • 4.3.7.1. Non-viral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Chemical
    • 4.4.1. Chemical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Physical
    • 4.5.1. Physical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Gene Delivery Technology Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Gene Delivery Technology Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Gene Therapy
    • 5.3.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cell Therapy
    • 5.4.1. Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Vaccines
    • 5.5.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Research
    • 5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Gene Delivery Technology Market: Method Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Gene Delivery Technology Market: Method Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Ex vivo
    • 6.3.1. Ex vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. In vivo
    • 6.4.1. In vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. In vitro
    • 6.5.1. In vitro Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Gene Delivery Technology Market: Regional Estimates & Trend Analysis

  • 7.1. Global Gene Delivery Technology Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. QIAGEN
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Horizon Discovery Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. OriGene Technologies, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Oxford Biomedica PLC
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. SignaGen Laboratories
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Flash Therapeutics
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Takara Bio Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bio-Rad Laboratories, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. System Biosciences, LLC.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Promega Corporation.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. F. Hoffmann-La Roche Ltd
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. SIRION BIOTECH GmbH
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. Catalent, Inc.
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives